Tag Archives: BIO CEO & Investor Conference

Small Biotech Companies and China: 5 Keys to Success

BIO CEO

Big pharmaceutical countries aren’t the only ones investing in China. Emerging and mid-sized biotech companies are also exploring ways to enter China’s lucrative market and maximize their investment in the country. With limited resources, how can smaller companies operate efficiently and give Chinese patients access to their innovative products? A panel of experts explored these questions at the 2013 BIO CEO & Investor Conference. Jimmy Zhang from Merck moderated a panel including: Friedhelm Blobel, PhD, President, CEO, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Despite Low Funding, Biotech Productivity Remains High In 2013

John Milligan

At the 2013 BIO CEO & Investor Conference, John Milligan, President and COO of Gilead Sciences, spoke in a standing room only fireside chat with Joel Sendek, Managing Director of Stifel Nicolaus, who moderated the discussion. Nicolaus noted that Gilead’s market cap has grown at an astounding 40 fold over the past 15 years, and asked Milligan to speak about the current state of the biotech industry. Milligan explained that biotech is not becoming more Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech

Tony Coles

After a stellar year, as evidenced by inclusion in the second annual FierceBiotech “25 Most Influential People in Bipoharma Today,” N. Anthony (Tony) Coles, MD, Chairman & CEO of Onyx Pharmaceuticals sat down with Steve Usdin, Senior Editor of BioCentury for an early morning Fireside Chat at the 15th Annual BIO CEO & Investor Conference. To read more about Onyx’s stellar year and their company milestones, visit here. The biotech retained complete control in the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Fireside Chat

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and they’re facing the losses of the antidepressant Cymbalta in December of 2013 and the osteoporosis drug Evista in 2014. The loss of protection endangers the company’s ability to profit from the drugs and they could face a $25 billion loss in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Word on the Street – Biotech Stocks Only Have Room to Go Up

The Opening Lunch Plenary at this year’s BIO CEO & Investor Conference was a lively discussion between portfolio managers and senior buy-side analysts looking to forecast the year ahead in biotech. BIO’s own, Celia Economides, Director, Investor Relations & Programs, reminded us all where we were 15 years ago at the inception of this event. At the 1999 event, there were 18 presenting companies, zero 1X1 meetings scheduled and 271 attendees.  As of day one, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,